• Corporate
  • About Medicago
  • Corporate strategy
  • Management team
  • Board of directors
  • Scientific advisory council
  • Current partnerships
• Technologies
  • Medicago technologies
  • Vaccines
    • Influenza
    • Pandemic market
  • Why Plants?
    • Tobacco
    • Alfalfa
  • Why Proficia™?
  • Why VLPs?
    • VLPExpress
  • Patents/IP
  • Scientific publications
• Manufacturing
  • Facility overview
  • Advantages
  • How does it work?
• Products
  • Product pipeline
  • Pandemic flu vaccine
  • Seasonal flu vaccine
  • Partnering opportunities
• Investors
  • Why invest
  • Stock quote
  • Events & presentations
  • Financial reports
  • Stockholder information
  • Analyst coverage
  • Corporate governance
  • Glossary of terms
  • IR contact
  • RSS feeds
• News
  • News releases
  • Medicago in the news
  • Useful links
• Partnerships
  • Current partnerships
  • Partnership opportunities
• Medicago USA
  • Medicago USA
  • Local Management Team
  • Partners
  • Photo Gallery

Investors

Why invest Stock quote Events & presentations Financial reports Stockholder information Analyst coverage Corporate governance Glossary of terms IR contact RSS feeds

Why Invest

• We have a disruptive technology; Rapid, cost-effective and easily scalable manufacturing solution
• We have advanced and robust clinical data; Positive Phase II data on pandemic flu vaccine & positive U.S. Phase I data on seasonal flu vaccine
• Our  technology platform offers differentiable advantages for Seasonal and Pandemic Influenza
• We have a strongly competitive cost of goods and capital expenditure model
• We have a successful International development strategy with near-term commercial opportunities

Français

• HOME
• CAREERS
• TERMS OF USE
• CONTACT US

Powered By Q4 Web Systems 3.5.18.3156